Drug Profile
Research programme: antibody therapeutics - LEO Science and Tech Hub/Elektrofi
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator LEO Science & Tech Hub
- Developer Elektrofi; LEO Science & Tech Hub
- Class Antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Skin-disorders in USA (SC)
- 09 Apr 2019 LEO Pharma and Elektrofi expand the research and development agreement to develop antibody therapeutics for Skin disorders
- 11 Oct 2017 LEO Pharma and Elektrofi agree to co-develop antibody therapeutics using advanced formulation technology for skin disorders